MannKind's Inhaled Insulin One Step Away From Approval...

April 2, 2014 10:27 AM

27 0

MannKind Corp.'s (MNKD: Quote) inhaled insulin, Afrezza, has cleared the penultimate regulatory hurdle in the U.S., following the FDA Advisory Committee's endorsement on Tuesday, and now awaits the big decision of final approval.

Afrezza, a drug-device combination product, is a novel, ultra rapid-acting mealtime insulin therapy to improve glycemic control in adult patients with type 1 or type 2 diabetes.

Read more

To category page